<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The increased number of cases of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (both diagnosed and undiagnosed) parallels the current epidemic of <z:hpo ids='HP_0001513'>obesity</z:hpo> in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>Despite receiving treatment, many patients do not achieve established therapeutic goals </plain></SENT>
<SENT sid="2" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is a progressive disease characterized by multiple abnormalities that extend beyond Î²-cell dysfunction and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Incretin-based agents, including glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become important options in the therapeutic paradigm for patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The author reviews physiologic mechanisms of the incretin system and discusses the practical application of GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> and DPP-4 inhibitors in improving GLP-1 dynamics in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>